Tobacco Rulings: Master Settlement, RICO Case, and FDA Law

The legal framework around cigarettes and other nicotine products in the United States was built through a small set of decisive events: the 1998 Master Settlement Agreement between state attorneys general and the major cigarette makers, a 2006 federal racketeering verdict against the industry, the 2009 law that finally gave the FDA authority over tobacco products, and a still-running series of FDA rulings and court decisions on e-cigarettes, synthetic nicotine, and graphic warning labels. Together these tobacco rulings govern how the products are marketed, packaged, approved, and sold at retail today.

The 1998 Master Settlement Agreement

The Master Settlement Agreement remains the largest civil litigation settlement in American history. In 1998, 52 state and territory attorneys general signed the MSA with the four largest cigarette manufacturers to resolve lawsuits seeking reimbursement for the public health costs of smoking-related illness.¹ The companies agreed to make annual payments to the settling states in perpetuity, so long as cigarettes continue to be sold in the country.

The MSA also rewrote the advertising rulebook. It banned cartoons in tobacco advertising, prohibited brand-name merchandise, ended tobacco sponsorship of events with significant youth audiences and of team sports, and blocked payments to place tobacco products in movies, television, and video games.¹ Joe Camel disappeared. NASCAR lost its Winston branding. Those restrictions have never been rolled back.

The 2006 Federal RICO Ruling

The federal government pushed further. In 2006, Judge Gladys Kessler ruled in United States v. Philip Morris USA, Inc. that nine cigarette manufacturers and two trade organizations had operated as a racketeering enterprise under the Racketeer Influenced and Corrupt Organizations Act.²

The court found “overwhelming evidence” of a decades-long coordinated fraud: denying that smoking caused disease, publicly questioning the science on secondhand smoke, concealing what the companies knew about nicotine’s addictiveness, marketing “light” and “low tar” cigarettes as safer when internal research said otherwise, and manipulating supposedly independent research to protect commercial interests.²

The remedies matched the finding. The court barred further racketeering or fraud, prohibited the “light” and “low tar” descriptors, ordered the reconstitution of certain joint industry organizations, and required the companies to maintain public depositories of internal documents produced during the litigation.²

The Corrective Statements

The most unusual remedy compelled the companies to publicly admit, in their own name, that they had misled the public. The corrective statements cover five topics: the adverse health effects of smoking, the addictiveness of nicotine, the false health claims about “light” and “low tar” cigarettes, the deliberate manipulation of cigarette design to enhance nicotine delivery, and the health effects of secondhand smoke.³

The statements ran on television and in newspapers during 2017 and 2018, went up on the companies’ corporate websites in November 2018 where they remain indefinitely, and appeared on cigarette package inserts through 2021. In 2023, a federal court ordered the same language to appear at the point of sale. Retailers with marketing agreements must display the signs near product shelving or checkout counters for 21 months.⁴

The 2009 Tobacco Control Act

Congress passed the Family Smoking Prevention and Tobacco Control Act in 2009, giving the FDA direct authority over the manufacture, marketing, and distribution of tobacco products for the first time.⁵ Before the act, the agency had no jurisdiction.

The act did four consequential things. It banned all characterizing flavors in cigarettes except menthol and tobacco, eliminating clove, cherry, vanilla and similar products that had appealed to younger smokers.⁶ It prohibited “light,” “mild,” and “low” in marketing unless the manufacturer obtained a modified-risk order from the FDA. It restricted advertising near schools and other places accessible to minors. And it created a premarket review system requiring FDA authorization before any new or modified tobacco product can be sold.⁵

Menthol was left in place. The FDA proposed a rule in April 2022 to prohibit menthol as a characterizing flavor in cigarettes, but the Trump administration withdrew the proposed rule in January 2025. A future administration could restart the process; for now, menthol cigarettes remain legal.⁷

Premarket Review, E-Cigarettes, and Synthetic Nicotine

Premarket review has become the FDA’s main gatekeeping tool. Any tobacco product not commercially marketed in the United States as of February 15, 2007, or any product modified after that date, needs FDA authorization before sale.⁸ Manufacturers file a Premarket Tobacco Product Application, and the FDA weighs whether marketing the product would be appropriate for the protection of public health, considering effects on current users, potential new users, and the overall population.

Vaping products have been hit hardest. The FDA has issued marketing denial orders for thousands of e-cigarettes, including well-known brands such as JUUL, certain Vuse products, myblu, Logic, and Hyde.⁹ Flavored e-cigarettes face particularly steep odds. In a single May 2023 action, the agency denied authorization for roughly 6,500 flavored products from ten companies.

Congress closed the synthetic-nicotine loophole in 2022 through the Consolidated Appropriations Act, extending FDA authority to nicotine from any source, including lab-made nicotine. Manufacturers of existing non-tobacco nicotine products had until May 14, 2022 to submit premarket applications; any product not on the market as of April 14, 2022 must receive marketing authorization before it can be sold at all.¹⁰

Graphic Warning Labels

The fight over graphic cigarette warnings has run through the courts for more than a decade. The Tobacco Control Act authorized the FDA to require large, graphic warnings on cigarette packages. The agency issued a revised rule in 2020 requiring color images depicting consequences like diseased lungs and oral cancer, covering the top 50 percent of packages. Manufacturers challenged the rule on First Amendment and administrative-procedure grounds.

In March 2024, the Fifth Circuit Court of Appeals ruled that the warnings were “factual and uncontroversial” and satisfied constitutional scrutiny, reversing the lower court on the First Amendment claim.¹¹ The Supreme Court declined to hear the industry’s appeal, leaving that ruling in place.

The warnings still are not on packs. The Fifth Circuit sent the remaining administrative-law claims back to the district court, which entered a preliminary injunction on January 14, 2025 postponing the rule’s effective date until final judgment in that ongoing litigation.¹² The constitutional question has been answered; the timing of actual enforcement has not.

Retailer Penalties for Tobacco Violations

Federal enforcement reaches down to the register. The FDA inspects retail locations and issues escalating penalties for violations such as selling tobacco to minors or stocking unauthorized products. The 2026 schedule, adjusted annually for inflation, works on a strike system:

First violation: warning letter, no fine
Second violation within 12 months: $365
Third violation within 24 months: $727
Fourth violation within 24 months: $2,920
Fifth violation within 36 months: $7,300
Sixth violation within 48 months: $14,602

The maximum penalty for a single violation involving unauthorized tobacco products is $21,903, and the FDA has stated it intends to seek that maximum in those cases.¹³ The early amounts are modest, but they compound quickly on a small retailer, and repeated violations can produce a no-tobacco-sale order that bars the store from selling any tobacco products.

1
National Association of Attorneys General. The Tobacco Master Settlement Agreement
2
U.S. Department of Justice. United States v Philip Morris USA Inc – Petition
3
National Cancer Institute. Corrective Statements Important Moment in Tobacco Control
4
U.S. Department of Justice. Court Issues Order Requiring Cigarette Companies to Post Corrective Statements
5
U.S. Congress. HR 1256 – 111th Congress – Family Smoking Prevention and Tobacco Control Act
6
Office of the Law Revision Counsel. 21 USC 387g – Tobacco Product Standards
7
Public Health Law Center. FDA Menthol Timeline
8
Office of the Law Revision Counsel. 21 USC 387j – Application for Review of Certain Tobacco Products
9
Food and Drug Administration. Tobacco Products Marketing Orders
10
Food and Drug Administration. Requirements for Products Made with Non-Tobacco Nicotine
11
U.S. Court of Appeals for the Fifth Circuit. RJ Reynolds Tobacco Co v FDA
12
Food and Drug Administration. Cigarette Labeling and Health Warning Requirements
13
Food and Drug Administration. Advisory and Enforcement Actions Against Industry for Selling Tobacco Products to Underage Purchasers